Menu Back toSession-14-Hot-Topics

Pharmacovigilance and Risk Management Strategies Conference

NEW! The 2019 meeting will be a full three days, allowing maximum learning opportunities!

Session 14: Hot Topics

Session Chair(s)

Mick Foy

Mick Foy

  • Group Manager, Vigilance Intelligence and Research Group
  • Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom
This session will inform attendees about the 3S project. Funded by the Bill and Melinda Gates the WHO are working with low and middle income countries with a high disease burden in specific areas that are subject to new treatments to increase their pharmacovigilance capabilities. MHRA are collaborating in the project to ensure regulatory pharmacovigilance capacity is increased to collect, analyse and act on safety data.
Learning Objective : Upon completion of this session, the participant should be able to:
    Understand the rationale for 3S
  • Learn how industry is key to the success of PV in low- and middle-income countries
  • Understand the need for robust regulatory frameworks for PV

Speaker(s)

Mick Foy

Mick Foy

  • Group Manager, Vigilance Intelligence and Research Group
  • Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom
Raj Long, MEd, MSc

Triple-s (3S) Smart Safety Surveillance

Raj Long, MEd, MSc

  • Senior Regulatory Officer, Integrated Development, Global Health
  • Bill and Melinda Gates Foundation, United Kingdom

Contact us

Customer Service

1.888.257.6457

Preconference Short Courses

Short Course 1: Introduction to Pharmacoepidemiology

Short Course 2: Pharmacovigilance and Risk Management Planning

Short Course 3: Reference Safety Information

Short Course 4: Combination Therapies

PVRMS Exhibitors

Exhibitor Directory